ClinicalTrials.gg
CompletedNCT00412984ARISTOTLEUpdated Jul 3, 2018Results posted

Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation

A Phase 3 interventional study of warfarin and apixaban in Atrial Fibrillation and Atrial Flutter, sponsored by Bristol-Myers Squibb. Completed at 1,113 sites in 41 countries. Per ClinicalTrials.gov, last updated 2018-07-03.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
20,976
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing apixaban in Atrial Fibrillation — 11 open to participants now, 12 under way, 4 of them phase 3. apixaban · Atrial Fibrillation.

Enrollment
Largest of 31
20,976 · median 586
Started
2006
the only one that year
Phase 3
12 of 31
4 open now
Registered
1st of 31
by date
Lead sponsor
3 of 31
Bristol-Myers Squibb

Among the 31 studies testing apixaban in Atrial Fibrillation, this one has the largest enrollment, is the only one that started in 2006, is one of 12 in phase 3, and was the 1st registered.

Atrial Fibrillation

4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

11 of the 31 studies testing apixaban in Atrial Fibrillation are open now, in 10 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About apixaban

apixaban: first FDA approval 2012 (ELIQUIS), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing apixaban in Atrial Fibrillation, or all of them as a file.
02

Study summary

The trial seeks to determine if apixaban, an investigational anticoagulant (blood-thinner) is as effective as standard therapy (warfarin) in preventing stroke and systemic embolism in subjects with atrial fibrillation and risk factors for stroke.

03

Conditions studied

  • Atrial Fibrillation
  • Atrial Flutter
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Males and females ≥ 18 yrs with atrial fibrillation (AF) and one or more of the following risk factors for stroke:
  • Age ≥ 75, previous stroke
  • (TIA) or Systemic Embolism (SE)
  • Symptomatic congestive heart failure or left ventricular dysfunction with (LVEF) ≤ 40%
  • Diabetes mellitus or hypertension requiring pharmacological treatment
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
20,976 participants (actual)

Study arms

  • Active comparator
    1

    Drug: warfarin

  • Experimental
    2

    Drug: apixaban

Interventions

  • Oral tablets, 2.0 mg, adjusted to an INR of 2.5 (range 2.0 to 3.0)

    Also known as: Coumadin, BMS-565793

  • Oral tablets, 5.0 mg or 2.5 mg, twice daily

    Also known as: BMS-562247

06

What researchers measure

Primary outcomes

  1. Number of Participants With First Event of Ischemic/Unspecified Stroke, Hemorrhagic Stroke, or Systemic Embolism (SE) During the Intended Treatment Period

    All suspected efficacy events were adjudicated by the Central Events Committee (CEC). Diagnosis of stroke=the nontraumatic focal neurological deficit lasting at least 24 hours, and includes ischemic stroke, hemorrhagic stroke, ischemic stroke with hemorrhagic conversion, stroke of uncertain type, and retinal ischemic event (embolism, infarction). Diagnosis of SE=clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), supported by evidence of embolism from surgical specimens, autopsy, angiography, vascular imaging, or other objective testing.

    Time frame: Time to first event in "Intended Treatment Period": started on day of randomization, ended at efficacy cut-off date (date target number of primary efficacy events [448] was expected to have occurred; set to 30-Jan-2011, prior to unblinding).

  2. Rate of Adjudicated Stroke or Systemic Embolism (SE) During the Intended Treatment Period

    Rate=Number of adjudicated stroke or SE events per 100 patient years. Diagnosis of stroke=the nontraumatic focal neurological deficit lasting at least 24 hours, and includes ischemic stroke, hemorrhagic stroke, ischemic stroke with hemorrhagic conversion, stroke of uncertain type, and retinal ischemic event (embolism, infarction). Diagnosis of SE=clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), supported by evidence of embolism from surgical specimens, autopsy, angiography, vascular imaging, or other objective testing.

    Time frame: "Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).

Secondary outcomes

  1. Number of Participants With Event of Major (International Society on Thrombosis and Hemostasis [ISTH]) Bleeding During Treatment Period

    ISTH Bleeding Criteria: Major bleeding=a bleeding event that was: clinically overt bleeding accompanied by a decrease in hemoglobin (Hgb) of 2 g/dL or more, and/or a transfusion of 2 or more units of packed red blood cells; bleeding that occurred in at least 1 of the following critical sites: intracranial, intraspinal, intraocular (within the corpus of the eye; a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, and retroperitoneal; bleeding that was fatal.

    Time frame: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.

  2. Rate of Adjudicated Major (ISTH) Bleed Events During Treatment Period

    Rate=number of adjudicated major (ISTH) bleed events per 100 patient years. ISTH Bleeding Criteria: Major bleeding=a bleeding event that was: clinically overt bleeding accompanied by a decrease in hemoglobin (Hgb) of 2 g/dL or more and/or a transfusion of 2 or more units of packed red blood cells; bleeding that occurred in at least 1 of the following sites: intracranial, intraspinal, intraocular (within the corpus of the eye; a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, and retroperitoneal; bleeding that was fatal.

    Time frame: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.

  3. Number of Participants With Events of All-Cause Death During the Intended Treatment Period

    Death was defined as all-cause mortality. All unobserved deaths were assumed to be cardiovascular in nature unless a non-cardiovascular cause could be clearly provided. Cardiovascular=deaths due to ischemic and hemorrhagic stroke, SE, myocardial infarction (MI), sudden death, heart failure, other cardiovascular, and unobserved deaths. Non-cardiovascular=all deaths due to a clearly documented non-cardiovascular cause (further classified into the categories: bleeding, study drug toxicity other than bleeding, malignancy, infection, trauma, and pulmonary causes of death).

    Time frame: "Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).

  4. Rate of Adjudicated All-Cause Death During the Intended Treatment Period

    All unobserved deaths were assumed to be cardiovascular in nature unless a non-cardiovascular cause could be clearly provided. Cardiovascular=deaths due to ischemic and hemorrhagic stroke, SE, MI, sudden death, heart failure, other cardiovascular, and unobserved deaths. Non-cardiovascular=all deaths due to a clearly documented non-cardiovascular cause (further classified into the categories: bleeding, study drug toxicity other than bleeding, malignancy, infection, trauma, and pulmonary causes of death).

    Time frame: "Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).

  5. Rate of Ischemic or Unspecified Stroke, Hemorrhagic Stroke, Systemic Embolism (SE), and Myocardial Infarction (MI) (as Individual Endpoints) During the Intended Treatment Period

    Diagnosis for an acute or evolving MI=elevation of creatine kinase-MB isoenzyme (CK-MB) or Troponin T or I ≥ 2 × the upper limit of normal (ULN), or if no CK-MB or troponin values are available, a total CK ≥ 2×ULN, or new, significant (≥0.04 s) Q waves in ≥2 contiguous leads. For descriptions of Stroke and SE, see Outcome Measure 1.

    Time frame: "Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).

  6. Rate of Ischemic or Unspecified Stroke, Hemorrhagic Stroke, Systemic Embolism (SE), Myocardial Infarction (MI) and All-Cause Death (ACD) (as Composite Endpoints) During the Intended Treatment Period

    Diagnosis for an acute or evolving MI=elevation of CK-MB or Troponin T or I ≥ 2 × the ULN, or if no CK-MB or troponin values are available, a total CK ≥ 2×ULN, or new, significant (≥0.04 s) Q waves in ≥2 contiguous leads. For descriptions of Stroke and SE, see Outcome Measure 1. For description of ACD, see Outcome Measure 5.

    Time frame: "Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).

  7. Number of Warfarin/Vitamin K Antagonist (VKA) Naive Participants With Composite Stroke / Systemic Embolism (SE) / Major Bleeding During the Intended Treatment Period

    For descriptions of Stroke and SE, see Outcome Measure 1. For description of Major bleeding, see Outcome Measure 3.

    Time frame: "Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).

  8. Rate of Composite Stroke / Systemic Embolism / Major Bleeding in Warfarin/Vitamin K Antagonist (VKA) Naive Participants During the Intended Treatment Period

    Time frame: "Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).

  9. Number of Participants With Events of Major or Clinically Relevant Nonmajor (CRNM) Bleed During Treatment Period

    Major bleeding=bleeding that is clinically overt and that either resulted in a decrease in hemoglobin of 2 g/dL or more over a 24-hour period, led to a transfusion of 2 or more units of packed red blood cells, occurred in a critical site, or led to death. CRNM bleeding=bleeding that is clinically overt, that satisfies none of the additional criteria required for the event to be adjudicated as a major bleeding event, that led to either hospital admission for bleeding, physician-guided medical or surgical treatment for bleeding, or a change in antithrombotic therapy.

    Time frame: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.

  10. Rate of Events of Major or Clinically Relevant Non-Major (CRNM) Bleed During Treatment Period

    Rate=number of major or CRNM bleed events per 100 patient years. Major=clinically overt and either 1) resulted in a decrease in hemoglobin of 2 g/dL or more, or 2) led to a transfusion of 2 or more units of packed red blood cells, or 3) occurred in a critical site, or 4) led to death. CRNM bleeding=clinically overt, but satisfied no additional criteria required to be adjudicated as a major bleeding event, and led to either 1) hospital admission for bleeding or 2) physician guided medical or surgical treatment for bleeding or 3) a change in antithrombotic therapy.

    Time frame: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.

  11. Number of Participants With All Bleeding Events During Treatment Period

    All bleeding events include major bleeding, CRNM bleeding (see Outcome Measure 12 Description for definitions), plus events of minor bleeding and fatal bleeding. Minor bleeding: All acute clinically overt bleeding events not meeting the criteria for either major bleeding or clinically relevant non-major bleeding will be classified as minor bleeding. Fatal bleeding is defined as a bleeding event that the Clinical Events Committee determines is the primary cause of death or contributes directly to death.

    Time frame: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.

  12. Rate of All Bleeding Events During Treatment Period

    Rate=number of all bleeding events per 100 patient years. "All bleeding events" include major bleeding, CRNM bleeding (see Outcome Measure 12 Description for definitions), plus events of minor bleeding and fatal bleeding. Minor bleeding: All acute clinically overt bleeding events not meeting the criteria for either major bleeding or clinically relevant non-major bleeding will be classified as minor bleeding. Fatal bleeding is defined as a bleeding event that the Clinical Events Committee determines is the primary cause of death or contributes directly to death.

    Time frame: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.

Other outcomes

  1. Number of Participants With Adverse Events (AEs), Bleeding AEs, Serious Adverse Events (SAEs), Discontinuations Due to AEs, or Deaths During the Treatment Period

    AE: all SAEs or AEs with onset from first dose through 2 days (AEs) or 30 days (SAEs) after the last dose of blinded study drug (BSD). SAE: all SAEs with onset from first dose through 30 days after the last dose of BSD. Bleeding AE: all serious or non-serious bleeding-related AEs with onset from first dose through 2 days after the last dose of BSD. Discontinuations due to AE: all SAEs or AEs with onset from first dose of BSD and with action taken=drug discontinued. Deaths: all deaths occurring from first dose through 30 days after the last dose of BSD.

    Time frame: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.

  2. Rate of Adjudicated Bleeding Endpoints Per Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) During the Treatment Period

    Rate=number of adjudicated GUSTO bleeding events per 100 patient years. GUSTO Bleeding Criteria: GUSTO severe (or life-threatening) bleeding: either intracranial hemorrhage or bleeding that causes hemodynamic compromise and requires intervention. GUSTO moderate bleeding: bleeding that requires blood transfusion but does not result in hemodynamic compromise.

    Time frame: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.

  3. Rate of Adjudicated Bleeding Endpoints Per Thrombolysis in Myocardial Infarction (TIMI) During the Treatment Period

    Rate=number of adjudicated TIMI bleeding events per 100 patient years. TIMI Bleeding Criteria: Major bleeding=Intracranial bleeding and/or clinically overt bleeding associated with ≥5 gm/dL fall in Hgb or 15% fall in hematocrit (Hct) from baseline, accounting for transfusions. Minor bleeding=Clinically overt bleeding associated with ≥3 gm/dL fall in Hgb or a ≥10% fall in Hct from baseline, accounting for transfusions.

    Time frame: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.

  4. Number of Participants With Net-Clinical Benefit During Treatment Period

    Net-Clinical Benefit = Composite of stroke, systemic embolism and ISTH major bleeding.

    Time frame: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.

  5. Rate of Net-Clinical Benefit During Treatment Period

    Rate=number of events of net-clinical benefit per 100 patient years. Net-Clinical Benefit = Composite of stroke, systemic embolism and ISTH major bleeding

    Time frame: "Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.

07

Results

Posted Apr 29, 2013

Participant flow

Participant flow — Overall Study
MilestoneApixabanWarfarin
Started91209081
Completed68106588
Not completed23102493
Withdrew: Death331349
Withdrew: Adverse event679738
Withdrew: Withdrawal by subject921989
Withdrew: Lost to follow-up5139
Withdrew: Poor/noncompliance5777
Withdrew: Pregnancy10
Withdrew: Subject no longer meets study criteria87100
Withdrew: Administrative reason by sponsor118
Withdrew: Physician refused to continue treatment8189
Withdrew: Other reason8092
Withdrew: Not reported1112

Outcome measures

PrimaryNumber of Participants With First Event of Ischemic/Unspecified Stroke, Hemorrhagic Stroke, or Systemic Embolism (SE) During the Intended Treatment Period

All suspected efficacy events were adjudicated by the Central Events Committee (CEC). Diagnosis of stroke=the nontraumatic focal neurological deficit lasting at least 24 hours, and includes ischemic stroke, hemorrhagic stroke, ischemic stroke with hemorrhagic conversion, stroke of uncertain type, and retinal ischemic event (embolism, infarction). Diagnosis of SE=clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), supported by evidence of embolism from surgical specimens, autopsy, angiography, vascular imaging, or other objective testing.

Time frame:
Time to first event in "Intended Treatment Period": started on day of randomization, ended at efficacy cut-off date (date target number of primary efficacy events [448] was expected to have occurred; set to 30-Jan-2011, prior to unblinding).
Reported as:
Number · participants
Number of Participants With First Event of Ischemic/Unspecified Stroke, Hemorrhagic Stroke, or Systemic Embolism (SE) During the Intended Treatment Period
participantsApixabanWarfarin
Ischemic or Unspecified Stroke159173
Hemorrhagic Stroke3876
Systemic Embolism1516
PrimaryRate of Adjudicated Stroke or Systemic Embolism (SE) During the Intended Treatment Period

Rate=Number of adjudicated stroke or SE events per 100 patient years. Diagnosis of stroke=the nontraumatic focal neurological deficit lasting at least 24 hours, and includes ischemic stroke, hemorrhagic stroke, ischemic stroke with hemorrhagic conversion, stroke of uncertain type, and retinal ischemic event (embolism, infarction). Diagnosis of SE=clinical history consistent with an acute loss of blood flow to a peripheral artery (or arteries), supported by evidence of embolism from surgical specimens, autopsy, angiography, vascular imaging, or other objective testing.

Time frame:
"Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
Reported as:
Number · Number of events per 100 patient years
Rate of Adjudicated Stroke or Systemic Embolism (SE) During the Intended Treatment Period
Number of events per 100 patient yearsApixabanWarfarin
Rate of Adjudicated Stroke or Systemic Embolism (SE) During the Intended Treatment Period1.271.60
Statistical analysis
  • Apixaban vs Warfarin · Cox Proportional Hazards Model · p = 0.0114 (2-sided P-value for superiority test) · Hazard ratio (hr): 0.79 · 95% CI .66 to .95apixaban / warfarin
SecondaryNumber of Participants With Event of Major (International Society on Thrombosis and Hemostasis [ISTH]) Bleeding During Treatment Period

ISTH Bleeding Criteria: Major bleeding=a bleeding event that was: clinically overt bleeding accompanied by a decrease in hemoglobin (Hgb) of 2 g/dL or more, and/or a transfusion of 2 or more units of packed red blood cells; bleeding that occurred in at least 1 of the following critical sites: intracranial, intraspinal, intraocular (within the corpus of the eye; a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, and retroperitoneal; bleeding that was fatal.

Time frame:
"Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
Reported as:
Number · participants
Number of Participants With Event of Major (International Society on Thrombosis and Hemostasis [ISTH]) Bleeding During Treatment Period
participantsApixabanWarfarin
Number of Participants With Event of Major (International Society on Thrombosis and Hemostasis [ISTH]) Bleeding During Treatment Period327462
SecondaryRate of Adjudicated Major (ISTH) Bleed Events During Treatment Period

Rate=number of adjudicated major (ISTH) bleed events per 100 patient years. ISTH Bleeding Criteria: Major bleeding=a bleeding event that was: clinically overt bleeding accompanied by a decrease in hemoglobin (Hgb) of 2 g/dL or more and/or a transfusion of 2 or more units of packed red blood cells; bleeding that occurred in at least 1 of the following sites: intracranial, intraspinal, intraocular (within the corpus of the eye; a conjunctival bleed is not an intraocular bleed), pericardial, intra-articular, intramuscular with compartment syndrome, and retroperitoneal; bleeding that was fatal.

Time frame:
"Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
Reported as:
Number · Number of events per 100 patient years
Rate of Adjudicated Major (ISTH) Bleed Events During Treatment Period
Number of events per 100 patient yearsApixabanWarfarin
Rate of Adjudicated Major (ISTH) Bleed Events During Treatment Period2.133.09
Statistical analysis
  • Apixaban vs Warfarin · Cox Proportional Hazards Model · p = <.0001 · Hazard ratio (hr): 0.69 · 95% CI 0.60 to 0.80apixaban / warfarin
SecondaryNumber of Participants With Events of All-Cause Death During the Intended Treatment Period

Death was defined as all-cause mortality. All unobserved deaths were assumed to be cardiovascular in nature unless a non-cardiovascular cause could be clearly provided. Cardiovascular=deaths due to ischemic and hemorrhagic stroke, SE, myocardial infarction (MI), sudden death, heart failure, other cardiovascular, and unobserved deaths. Non-cardiovascular=all deaths due to a clearly documented non-cardiovascular cause (further classified into the categories: bleeding, study drug toxicity other than bleeding, malignancy, infection, trauma, and pulmonary causes of death).

Time frame:
"Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
Reported as:
Number · participants
Number of Participants With Events of All-Cause Death During the Intended Treatment Period
participantsApixabanWarfarin
Number of Participants With Events of All-Cause Death During the Intended Treatment Period603669
SecondaryRate of Adjudicated All-Cause Death During the Intended Treatment Period

All unobserved deaths were assumed to be cardiovascular in nature unless a non-cardiovascular cause could be clearly provided. Cardiovascular=deaths due to ischemic and hemorrhagic stroke, SE, MI, sudden death, heart failure, other cardiovascular, and unobserved deaths. Non-cardiovascular=all deaths due to a clearly documented non-cardiovascular cause (further classified into the categories: bleeding, study drug toxicity other than bleeding, malignancy, infection, trauma, and pulmonary causes of death).

Time frame:
"Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
Reported as:
Number · Number of events per 100 patient years
Rate of Adjudicated All-Cause Death During the Intended Treatment Period
Number of events per 100 patient yearsApixabanWarfarin
Rate of Adjudicated All-Cause Death During the Intended Treatment Period3.523.94
Statistical analysis
  • Apixaban vs Warfarin · Cox Proportional Hazards Model · p = 0.0465 · Hazard ratio (hr): 0.89 · 95% CI 0.80 to 1.00apixaban / warfarin
SecondaryRate of Ischemic or Unspecified Stroke, Hemorrhagic Stroke, Systemic Embolism (SE), and Myocardial Infarction (MI) (as Individual Endpoints) During the Intended Treatment Period

Diagnosis for an acute or evolving MI=elevation of creatine kinase-MB isoenzyme (CK-MB) or Troponin T or I ≥ 2 × the upper limit of normal (ULN), or if no CK-MB or troponin values are available, a total CK ≥ 2×ULN, or new, significant (≥0.04 s) Q waves in ≥2 contiguous leads. For descriptions of Stroke and SE, see Outcome Measure 1.

Time frame:
"Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
Reported as:
Number · Number of events per 100 patient years
Rate of Ischemic or Unspecified Stroke, Hemorrhagic Stroke, Systemic Embolism (SE), and Myocardial Infarction (MI) (as Individual Endpoints) During the Intended Treatment Period
Number of events per 100 patient yearsApixabanWarfarin
Ischemic or Unspecified Stroke (n=162, 175)0.971.05
Hemorrhagic Stroke (n=40, 78)0.240.47
Systemic Embolism (n=15, 17)0.090.10
Myocardial Infarction (n=90, 102)0.530.61
Statistical analysis
  • Apixaban vs Warfarin · Cox Proportional Hazards Model · p = 0.4220 (nominal two-sided p-value was associated with a test of H0: RR=1 vs H1: RR ≠ 1) · Hazard ratio (hr): 0.92 · 95% CI 0.74 to 1.13apixaban / warfarin
  • Apixaban vs Warfarin · Cox Proportional Hazards Model · p = 0.0006 (nominal two-sided p-value was associated with a test of H0: RR=1 vs H1: RR ≠ 1) · Hazard ratio (hr): 0.51 · 95% CI 0.35 to 0.75apixaban / warfarin
  • Apixaban vs Warfarin · Cox Proportional Hazards Model · p = 0.7020 (nominal two-sided p-value was associated with a test of H0: RR=1 vs H1: RR ≠ 1) · Hazard ratio (hr): 0.87 · 95% CI 0.44 to 1.75apixaban / warfarin
  • Apixaban vs Warfarin · Cox Proportional Hazards Model · p = 0.3720 (nominal two-sided p-value was associated with a test of H0: RR=1 vs H1: RR ≠ 1) · Hazard ratio (hr): 0.88 · 95% CI 0.66 to 1.17apixaban / warfarin
SecondaryRate of Ischemic or Unspecified Stroke, Hemorrhagic Stroke, Systemic Embolism (SE), Myocardial Infarction (MI) and All-Cause Death (ACD) (as Composite Endpoints) During the Intended Treatment Period

Diagnosis for an acute or evolving MI=elevation of CK-MB or Troponin T or I ≥ 2 × the ULN, or if no CK-MB or troponin values are available, a total CK ≥ 2×ULN, or new, significant (≥0.04 s) Q waves in ≥2 contiguous leads. For descriptions of Stroke and SE, see Outcome Measure 1. For description of ACD, see Outcome Measure 5.

Time frame:
"Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
Reported as:
Number · Number of events per 100 patient years
Rate of Ischemic or Unspecified Stroke, Hemorrhagic Stroke, Systemic Embolism (SE), Myocardial Infarction (MI) and All-Cause Death (ACD) (as Composite Endpoints) During the Intended Treatment Period
Number of events per 100 patient yearsApixabanWarfarin
Stroke / SE / Major Bleeding (n=521, 666)3.174.11
Stroke / SE / All-Cause Death (ACD) (n=752, 837)4.495.04
Stroke / SE / Major Bleeding / ACD (n=1009, 1168)6.137.20
Stroke / SE / MI / ACD (n=810, 906)4.855.49
Ischemic or Unspecified Stroke / ACD (n=725, 796)4.324.78
Hemorrhagic Stroke / ACD (n=622, 703)3.684.20
SE / ACD (n=613, 679)3.634.05
MI / ACD (n=663, 740)3.934.43
Statistical analysis
  • Apixaban vs Warfarin · Cox Proportional Hazards Model · p = <.0001 (nominal two-sided p-value was associated with a test of H0: RR=1 vs H1: RR ≠ 1) · Hazard ratio (hr): 0.77 · 95% CI 0.69 to 0.86apixaban / warfarin
  • Apixaban vs Warfarin · Cox Proportional Hazards Model · p = 0.0192 (nominal two-sided p-value was associated with a test of H0: RR=1 vs H1: RR ≠ 1) · Hazard ratio (hr): 0.89 · 95% CI 0.81 to 0.98apixaban / warfarin
  • Apixaban vs Warfarin · Cox Proportional Hazards Model · p = 0.0002 (nominal two-sided p-value was associated with a test of H0: RR=1 vs H1: RR ≠ 1) · Hazard ratio (hr): 0.85 · 95% CI 0.78 to 0.92apixaban / warfarin
  • Apixaban vs Warfarin · Cox Proportional Hazards Model · p = 0.0107 (nominal two-sided p-value was associated with a test of H0: RR=1 vs H1: RR ≠ 1) · Hazard ratio (hr): 0.88 · 95% CI 0.80 to 0.97apixaban / warfarin
  • Apixaban vs Warfarin · Cox Proportional Hazards Model · p = 0.0432 (nominal two-sided p-value was associated with a test of H0: RR=1 vs H1: RR ≠ 1) · Hazard ratio (hr): 0.90 · 95% CI 0.82 to 1.00apixaban / warfarin
  • Apixaban vs Warfarin · Cox Proportional Hazards Model · p = 0.0167 (nominal two-sided p-value was associated with a test of H0: RR=1 vs H1: RR ≠ 1) · Hazard ratio (hr): 0.88 · 95% CI 0.79 to 0.98apixaban / warfarin
  • Apixaban vs Warfarin · Cox Proportional Hazards Model · p = 0.0464 (nominal two-sided p-value was associated with a test of H0: RR=1 vs H1: RR ≠ 1) · Hazard ratio (hr): 0.89 · 95% CI 0.80 to 1.00apixaban / warfarin
  • Apixaban vs Warfarin · Cox Proportional Hazards Model · p = 0.0253 (nominal two-sided p-value was associated with a test of H0: RR=1 vs H1: RR ≠ 1) · Hazard ratio (hr): 0.89 · 95% CI 0.80 to 0.99apixaban / warfarin
SecondaryNumber of Warfarin/Vitamin K Antagonist (VKA) Naive Participants With Composite Stroke / Systemic Embolism (SE) / Major Bleeding During the Intended Treatment Period

For descriptions of Stroke and SE, see Outcome Measure 1. For description of Major bleeding, see Outcome Measure 3.

Time frame:
"Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
Reported as:
Number · participants
Number of Warfarin/Vitamin K Antagonist (VKA) Naive Participants With Composite Stroke / Systemic Embolism (SE) / Major Bleeding During the Intended Treatment Period
participantsApixabanWarfarin
Number of Warfarin/Vitamin K Antagonist (VKA) Naive Participants With Composite Stroke / Systemic Embolism (SE) / Major Bleeding During the Intended Treatment Period229285
SecondaryRate of Composite Stroke / Systemic Embolism / Major Bleeding in Warfarin/Vitamin K Antagonist (VKA) Naive Participants During the Intended Treatment Period
Time frame:
"Intended Treatment Period" started on the day of randomization and ended at the efficacy cut-off date (date on which it was expected that the target number of primary efficacy events [448] would have occurred; set to 30-Jan-2011, prior to unblinding).
Reported as:
Number · Number of events per 100 patient years
Rate of Composite Stroke / Systemic Embolism / Major Bleeding in Warfarin/Vitamin K Antagonist (VKA) Naive Participants During the Intended Treatment Period
Number of events per 100 patient yearsApixabanWarfarin
Rate of Composite Stroke / Systemic Embolism / Major Bleeding in Warfarin/Vitamin K Antagonist (VKA) Naive Participants During the Intended Treatment Period3.214.06
Statistical analysis
  • Apixaban vs Warfarin · Cox Proportional Hazards Model · p = 0.0098 (nominal two-sided p-value was associated with a test of H0: RR=1 vs H1: RR ≠ 1) · Hazard ratio (hr): 0.80 · 95% CI 0.67 to 0.95apixaban / warfarin
Other pre-specifiedNumber of Participants With Adverse Events (AEs), Bleeding AEs, Serious Adverse Events (SAEs), Discontinuations Due to AEs, or Deaths During the Treatment Period

AE: all SAEs or AEs with onset from first dose through 2 days (AEs) or 30 days (SAEs) after the last dose of blinded study drug (BSD). SAE: all SAEs with onset from first dose through 30 days after the last dose of BSD. Bleeding AE: all serious or non-serious bleeding-related AEs with onset from first dose through 2 days after the last dose of BSD. Discontinuations due to AE: all SAEs or AEs with onset from first dose of BSD and with action taken=drug discontinued. Deaths: all deaths occurring from first dose through 30 days after the last dose of BSD.

Time frame:
"Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs), Bleeding AEs, Serious Adverse Events (SAEs), Discontinuations Due to AEs, or Deaths During the Treatment Period
participantsApixabanWarfarin
AE74067521
SAE31823302
Bleeding AE22882961
Discontinuations due to AE688758
Deaths429468
SecondaryNumber of Participants With Events of Major or Clinically Relevant Nonmajor (CRNM) Bleed During Treatment Period

Major bleeding=bleeding that is clinically overt and that either resulted in a decrease in hemoglobin of 2 g/dL or more over a 24-hour period, led to a transfusion of 2 or more units of packed red blood cells, occurred in a critical site, or led to death. CRNM bleeding=bleeding that is clinically overt, that satisfies none of the additional criteria required for the event to be adjudicated as a major bleeding event, that led to either hospital admission for bleeding, physician-guided medical or surgical treatment for bleeding, or a change in antithrombotic therapy.

Time frame:
"Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
Reported as:
Number · participants
Number of Participants With Events of Major or Clinically Relevant Nonmajor (CRNM) Bleed During Treatment Period
participantsApixabanWarfarin
Number of Participants With Events of Major or Clinically Relevant Nonmajor (CRNM) Bleed During Treatment Period613877
SecondaryRate of Events of Major or Clinically Relevant Non-Major (CRNM) Bleed During Treatment Period

Rate=number of major or CRNM bleed events per 100 patient years. Major=clinically overt and either 1) resulted in a decrease in hemoglobin of 2 g/dL or more, or 2) led to a transfusion of 2 or more units of packed red blood cells, or 3) occurred in a critical site, or 4) led to death. CRNM bleeding=clinically overt, but satisfied no additional criteria required to be adjudicated as a major bleeding event, and led to either 1) hospital admission for bleeding or 2) physician guided medical or surgical treatment for bleeding or 3) a change in antithrombotic therapy.

Time frame:
"Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
Reported as:
Number · number of events / 100 patient years
Rate of Events of Major or Clinically Relevant Non-Major (CRNM) Bleed During Treatment Period
number of events / 100 patient yearsApixabanWarfarin
Rate of Events of Major or Clinically Relevant Non-Major (CRNM) Bleed During Treatment Period4.076.01
Statistical analysis
  • Apixaban vs Warfarin · Cox Proportional Hazard Model · p = <.0001 (nominal two-sided p-value was associated with a test of H0: RR=1 vs H1: RR ≠ 1) · Hazard ratio (hr): 0.68 · 95% CI 0.61 to 0.75apixaban / warfarin
SecondaryNumber of Participants With All Bleeding Events During Treatment Period

All bleeding events include major bleeding, CRNM bleeding (see Outcome Measure 12 Description for definitions), plus events of minor bleeding and fatal bleeding. Minor bleeding: All acute clinically overt bleeding events not meeting the criteria for either major bleeding or clinically relevant non-major bleeding will be classified as minor bleeding. Fatal bleeding is defined as a bleeding event that the Clinical Events Committee determines is the primary cause of death or contributes directly to death.

Time frame:
"Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
Reported as:
Number · participants
Number of Participants With All Bleeding Events During Treatment Period
participantsApixabanWarfarin
Number of Participants With All Bleeding Events During Treatment Period23563060
SecondaryRate of All Bleeding Events During Treatment Period

Rate=number of all bleeding events per 100 patient years. "All bleeding events" include major bleeding, CRNM bleeding (see Outcome Measure 12 Description for definitions), plus events of minor bleeding and fatal bleeding. Minor bleeding: All acute clinically overt bleeding events not meeting the criteria for either major bleeding or clinically relevant non-major bleeding will be classified as minor bleeding. Fatal bleeding is defined as a bleeding event that the Clinical Events Committee determines is the primary cause of death or contributes directly to death.

Time frame:
"Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
Reported as:
Number · number of events per 100 patient years
Rate of All Bleeding Events During Treatment Period
number of events per 100 patient yearsApixabanWarfarin
Rate of All Bleeding Events During Treatment Period18.0825.82
Statistical analysis
  • Apixaban vs Warfarin · Cox Proportional Hazard Model · p = <.0001 (nominal two-sided p-value was associated with a test of H0: RR=1 vs H1: RR ≠ 1) · Hazard ratio (hr): 0.71 · 95% CI 0.68 to 0.75apixaban / warfarin
Other pre-specifiedRate of Adjudicated Bleeding Endpoints Per Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) During the Treatment Period

Rate=number of adjudicated GUSTO bleeding events per 100 patient years. GUSTO Bleeding Criteria: GUSTO severe (or life-threatening) bleeding: either intracranial hemorrhage or bleeding that causes hemodynamic compromise and requires intervention. GUSTO moderate bleeding: bleeding that requires blood transfusion but does not result in hemodynamic compromise.

Time frame:
"Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
Reported as:
Number · Number of events per 100 patient years
Rate of Adjudicated Bleeding Endpoints Per Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) During the Treatment Period
Number of events per 100 patient yearsApixabanWarfarin
Severe (n=80, 172))0.521.13
Severe or Moderate (n=199, 328)1.292.18
Statistical analysis
  • Apixaban vs Warfarin · Cox Proportional Hazard Model · p = <.0001 (nominal two-sided p-value was associated with a test of H0: RR=1 vs H1: RR ≠ 1) · Hazard ratio (hr): 0.46 · 95% CI 0.35 to 0.60apixaban / warfarin
  • Apixaban vs Warfarin · Cox Proportional Hazard Model · p = <.0001 (nominal two-sided p-value was associated with a test of H0: RR=1 vs H1: RR ≠ 1) · Hazard ratio (hr): 0.60 · 95% CI 0.50 to 0.71apixaban / warfarin
Other pre-specifiedRate of Adjudicated Bleeding Endpoints Per Thrombolysis in Myocardial Infarction (TIMI) During the Treatment Period

Rate=number of adjudicated TIMI bleeding events per 100 patient years. TIMI Bleeding Criteria: Major bleeding=Intracranial bleeding and/or clinically overt bleeding associated with ≥5 gm/dL fall in Hgb or 15% fall in hematocrit (Hct) from baseline, accounting for transfusions. Minor bleeding=Clinically overt bleeding associated with ≥3 gm/dL fall in Hgb or a ≥10% fall in Hct from baseline, accounting for transfusions.

Time frame:
"Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
Reported as:
Number · Number of events per 100 patient years
Rate of Adjudicated Bleeding Endpoints Per Thrombolysis in Myocardial Infarction (TIMI) During the Treatment Period
Number of events per 100 patient yearsApixabanWarfarin
Major (n=148, 256)0.961.69
Major or Minor (n=239, 370)1.552.46
Statistical analysis
  • Apixaban vs Warfarin · Cox Proportional Hazard Model · p = <.0001 (nominal two-sided p-value was associated with a test of H0: RR=1 vs H1: RR ≠ 1) · Hazard ratio (hr): 0.57 · 95% CI 0.46 to 0.70apixaban / warfarin
  • Apixaban vs Warfarin · Cox Proportional Hazard Model · p = <.0001 · Hazard ratio (hr): 0.63 · 95% CI 0.54 to 0.75apixaban / warfarin
Other pre-specifiedNumber of Participants With Net-Clinical Benefit During Treatment Period

Net-Clinical Benefit = Composite of stroke, systemic embolism and ISTH major bleeding.

Time frame:
"Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
Reported as:
Number · participants
Number of Participants With Net-Clinical Benefit During Treatment Period
participantsApixabanWarfarin
Number of Participants With Net-Clinical Benefit During Treatment Period459608
Other pre-specifiedRate of Net-Clinical Benefit During Treatment Period

Rate=number of events of net-clinical benefit per 100 patient years. Net-Clinical Benefit = Composite of stroke, systemic embolism and ISTH major bleeding

Time frame:
"Treatment Period" started with first dose of blinded study drug and ended 2 days after the last dose of blinded study drug. Mean duration of exposure to double-blind study drug was 1.7 years in each treatment group.
Reported as:
Number · Number of events per 100 patient years
Rate of Net-Clinical Benefit During Treatment Period
Number of events per 100 patient yearsApixabanWarfarin
Rate of Net-Clinical Benefit During Treatment Period3.014.09
Statistical analysis
  • Apixaban vs Warfarin · Cox Proportional Hazard Model · p = <.0001 (nominal two-sided p-value was associated with a test of H0: RR=1 vs H1: RR ≠ 1) · Hazard ratio (hr): 0.74 · 95% CI 0.65 to 0.83apixaban / warfarin

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Warfarin—3,182/9,088 (35%)3,876/9,088 (42.6%)
Apixaban—3,302/9,052 (36.5%)4,071/9,052 (45%)
Most frequent serious events
Showing 10 of 1,432
Most frequent serious events
EventWarfarinApixaban
Cardiac failureCardiac disorders310/9088301/9052
Atrial fibrillationCardiac disorders301/9088287/9052
PneumoniaInfections and infestations202/9088231/9052
Cardiac failure congestiveCardiac disorders171/9088175/9052
Angina unstableCardiac disorders112/908887/9052
Ischaemic strokeNervous system disorders91/908876/9052
Myocardial infarctionCardiac disorders80/908863/9052
SyncopeNervous system disorders79/908849/9052
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders68/908876/9052
Chest painGeneral disorders43/908872/9052
Most frequent other events
Showing 10 of 13
Most frequent other events
EventWarfarinApixaban
NasopharyngitisInfections and infestations763/9088779/9052
DizzinessNervous system disorders654/9088702/9052
EpistaxisRespiratory, thoracic and mediastinal disorders547/9088666/9052
Oedema peripheralGeneral disorders607/9088661/9052
DyspnoeaRespiratory, thoracic and mediastinal disorders583/9088633/9052
DiarrhoeaGastrointestinal disorders580/9088581/9052
CoughRespiratory, thoracic and mediastinal disorders493/9088505/9052
Back painMusculoskeletal and connective tissue disorders428/9088502/9052
Urinary tract infectionInfections and infestations471/9088501/9052
BronchitisInfections and infestations473/9088493/9052

Baseline characteristics

Randomized participants

Age, Continuous
Age, Continuous(years)ApixabanWarfarinTotal
Mean69.1 ± 9.6169.0 ± 9.7469.1 ± 9.68
Age, Customized
Age, Customized(Participants)ApixabanWarfarinTotal
<65 years273127405471
Between 65 and 75 years353935137052
>=75 years285028285678
Sex: Female, Male
Sex: Female, Male(Participants)ApixabanWarfarinTotal
Female323431826416
Male5886589911785
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ApixabanWarfarinTotal
White (European)5440536610806
White (Middle Eastern or North African)5966125
White (Other White)203720604097
White (Not Reported)011
Black / African American125102227
Asian (Asian Indian)307312619
Asian (Chinese)5365361072
Asian (Japanese)164180344
Asian (Other Asian)303304607
American Indian / Alaska Native262450
Native Hawaiian / Other Pacific Islander224
Other121127248
Not Reported011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ApixabanWarfarinTotal
Hispanic / Latino180818033611
Not Hispanic / Latino7312727614588
Not Reported022
Female Age Category
Female Age Category(Participants)ApixabanWarfarinTotal
<=50 years8188169
>50 years315330946247
not applicable (male)5886589911785
Apixaban/Matching Placebo Dose at Randomization
Apixaban/Matching Placebo Dose at Randomization(Participants)ApixabanWarfarinTotal
2.5 mg twice daily (BID)428403831
5.0 mg BID8692867817370
Risk Factor at Enrollment: Age >= 75 Years
Risk Factor at Enrollment: Age >= 75 Years(Participants)ApixabanWarfarinTotal
>=75 years285028285678
<75 years6270625312523

7 further baseline measures are reported on the registry.

08

Study locations

1,113 sites
  • Cardiovascular Associates, Pc
    Birmingham, Alabama 35209, United States
  • Alabama Internal Medicine Pc
    Birmingham, Alabama 35235, United States
  • Birmingham Heart Clinic P.C.
    Birmingham, Alabama 35235, United States
  • Heart Center, Inc.
    Huntsville, Alabama 35801, United States
  • Mobile Heart Specialists, Pc
    Mobile, Alabama 36608, United States
  • Clara V. Massey, Md
    Mobile, Alabama 36617, United States
  • Alaska Heart Institute
    Anchorage, Alaska 99508, United States
  • Internal Medicine Physicians Associates, P.C.
    Phoenix, Arizona 85006, United States
  • Southwest Heart
    Tucson, Arizona 85710, United States
  • Southern Arizona Va Health Care System
    Tucson, Arizona 85723, United States
  • Pima Research Foundation
    Tucson, Arizona 85745, United States
  • Dr. Rajesh Shroff
    Hot Springs, Arkansas 71913, United States
  • Mary K. Richards, Md Pa
    Little Rock, Arkansas 72204, United States
  • Advanced Clinical Reserach Institute
    Anaheim, California 92801, United States
  • Act/Cardiovascular Research Institute
    Beverly Hills, California 90210, United States
  • Capitol Interventional Cardiology
    Carmichael, California 95608, United States
  • Escondido Cardiology Associates, Inc.
    Escondido, California 92025, United States
  • William D. Bowden, D.O.
    Healdsburg, California 95448, United States
  • La Mesa Cardiac Center, A Medical Group
    La Mesa, California 91942, United States
  • Va Greater Los Angeles Healthcare System
    Los Angeles, California 90073, United States
  • Coastal Cardiology
    Mission Viejo, California 92691, United States
  • Kenneth W. Carr Md
    Oceanside, California 92056, United States
  • Desert Med Grp Inc, Dba Desert Oasis Healthcare Med Group
    Palm Springs, California 92262, United States
  • Desert Cardiology Consultants Medical Group, Inc
    Rancho Mirage, California 92270, United States
  • Regional Cardiolody Associates
    Sacramento, California 95819, United States
  • Northern California Research
    Sacramento, California 95821, United States
  • Sacramento Heart And Vascular Medical Associates
    Sacramento, California 95825, United States
  • Arrhythmia Consultants Of The Central Coast Medical Group
    Santa Barbara, California 93105, United States
  • Northern California Medical Associates
    Santa Rosa, California 95403, United States
  • Progressive Clinical Research
    Vista, California 92083, United States
  • Cardivasclular Consultants Medical Group
    Walnut Creek, California 94598, United States
  • Shiva Heart Center Medical Group
    Wildomar, California 92595, United States
  • Electrophysiology Associates, Pc
    Colorado Springs, Colorado 80910, United States
  • Aurora Denver Cardiology Associates, P.C.
    Denver, Colorado 80218, United States
  • Denver Va Medical Center
    Denver, Colorado 80220, United States
  • New West Physicians Clinical Research
    Golden, Colorado 80401, United States
  • South Denver Cardiology Associates Pc
    Littleton, Colorado 80120, United States
  • Connecticut Clinical Research, Llc
    Bridgeport, Connecticut 06606, United States
  • Bridgeport Hospital
    Bridgeport, Connecticut 06610, United States
  • Cardiology Associates Of New Haven,Pc
    Guilford, Connecticut 06437, United States
  • The William W. Backus Hospital
    Norwich, Connecticut 06360, United States
  • William W Backus Hospital
    Norwich, Connecticut 06360, United States
  • Stamford Therapeutics Consortium
    Stamford, Connecticut 06905, United States
  • Chase Medical Research, Llc
    Waterbury, Connecticut 06708, United States
  • Alfieri Cardiology
    Newark, Delaware 19713, United States
  • George Washington University Medical Faculty Associates
    Washington, District of Columbia 20037, United States
  • Washington Va Medical Center
    Washington, District of Columbia 20422, United States
  • Medical Specialist Of The Palm Beach
    Atlantis, Florida 33462, United States
  • Miami International Cardiology Consultants
    Aventura, Florida 33180, United States
  • David Charles Mishkel, Md, Pa
    Boca Raton, Florida 33431, United States
  • The Heart & Vascular Institute Of Florida
    Clearwater, Florida 33756, United States
  • The Heart And Vascular Institute Of Florida
    Clearwater, Florida 33756, United States
  • Cardiovascular Specialist Of South Florida
    Davie, Florida 33324, United States
  • Daytona Heart Group
    Daytona Beach, Florida 32114, United States
  • Cardiology Associates Of Fort Lauderdale, P.A.
    Fort Lauderdale, Florida 33308, United States
  • Broward General Medical Center
    Fort Lauderdale, Florida 33316, United States
  • Florida Heart Associates
    Fort Myers, Florida 33907, United States
  • Florida Research Network, Llc
    Gainesville, Florida 32605, United States
  • Healthworx
    Hollywood, Florida 33021, United States
  • Luis Tami, Md
    Hollywood, Florida 33021, United States
  • Nature Coast Clinical Research
    Inverness, Florida 34452, United States
  • Jacksonville Heart Center, P.A.
    Jacksonville Beach, Florida 32250, United States
  • St. Vincent'S Ambulatory Care, Inc
    Jacksonville, Florida 32204, United States
  • Jacksonville Heart Center, Pa
    Jacksonville, Florida 32207, United States
  • Jacksonville Cardiovascular Center
    Jacksonville, Florida 32216, United States
  • Jacksonville Center For Clinical Research
    Jacksonville, Florida 32216, United States
  • St. Luke'S Cardiology
    Jacksonville, Florida 32216, United States
  • Jacksonville Heart Center, Pa
    Jacksonville, Florida 32258, United States
  • Cvms Research Institute, Llc
    Jupiter, Florida 33458, United States
  • Ricardo Bedoya, M.D.
    Jupiter, Florida 33458, United States
  • Melbourne Internal Medicine Associates
    Melbourne, Florida 32901, United States
  • Miami International Cardiology Consultants
    Miami, Florida 33137-3732, United States
  • Miami International Cardiology Consultants
    Miami, Florida 33137, United States
  • Physicians Regional Medical Group
    Naples, Florida 34119, United States
  • Florida Heart Group
    Orlando, Florida 32803, United States
  • Alpha Medical Research
    Oviedo, Florida 32765, United States
  • Cardiology Consultants
    Pensacola, Florida 32501, United States
  • The Heart And Vascular Institute Of Florida
    Saint Petersburg, Florida 33709, United States
  • Niranjan Seshadri, Md
    Sarasota, Florida 34232, United States
  • Heart & Vascular Center Research, Inc.
    Sarasota, Florida 34239, United States
  • Research, Inc.
    Vero Beach, Florida 32960, United States
  • Cardiovascular Specialits, Pc
    Atlanta, Georgia 30342, United States
  • Augusta Cardiology Clinic, P.C.
    Augusta, Georgia 30901, United States
  • Columbus Cardiology Associates Pc
    Columbus, Georgia 31909, United States
  • Columbus Cardiology Associates,Pc
    Columbus, Georgia 31909, United States
  • Georgia Heart Specialists, L.L.C.
    Covington, Georgia 30014, United States
  • Atlanta Institute For Medical Research, Inc
    Decatur, Georgia 30030, United States
  • Northeast Georgia Heart Center, Pc
    Gainesville, Georgia 30501, United States
  • Wellstar Cardiovascular Medicine, Pc
    Marietta, Georgia 30060, United States
  • Fox Valley Clinical Research Center, Llc
    Aurora, Illinois 60504, United States
  • Nmff
    Chicago, Illinois 60611, United States
  • Clinical Investigation Specialists, Inc
    Gurnee, Illinois 60031, United States
  • Loyola University Medical Center
    Maywood, Illinois 60153, United States
  • Illinois Heart & Lung Research Center, Sc
    Normal, Illinois 61761, United States
  • Cpt. James A Lovell Federal Health Care Center
    North Chicago, Illinois 60064, United States
  • Community Clinical Research Center
    Anderson, Indiana 46011, United States
  • Premier Healthcare, Llc
    Bloomington, Indiana 47403, United States
  • Elkhart Clinic, Llc
    Elkhart, Indiana 46514, United States
  • Lutheran Medical Group, Llc
    Fort Wayne, Indiana 46804, United States
  • Fort Wayne Cardiology
    Fort Wayne, Indiana 46805, United States

Showing the first 100 of 1,113 sites across 41 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Jamieson MJ, Byon W, Dettloff RW, Crawford M, Gargalovic PS, Merali SJ, Onorato J, Quintero AJ, Russ C. Apixaban Use in Obese Patients: A Review of the Pharmacokinetic, Interventional, and Observational Study Data. Am J Cardiovasc Drugs. 2022 Nov;22(6):615-631. doi: 10.1007/s40256-022-00524-x. Epub 2022 May 16. PubMed 35570249 ↗
  • Pol T, Hijazi Z, Lindback J, Oldgren J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Granger CB, Lopes RD, Yusuf S, Siegbahn A, Wallentin L. Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation. Cardiovasc Res. 2022 Jul 20;118(9):2112-2123. doi: 10.1093/cvr/cvab262. PubMed 34358298 ↗
  • Pol T, Hijazi Z, Lindback J, Alexander JH, Bahit MC, De Caterina R, Eikelboom JW, Ezekowitz MD, Gersh BJ, Granger CB, Hylek EM, Lopes R, Siegbahn A, Wallentin L. Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas. Open Heart. 2021 Mar;8(1):e001471. doi: 10.1136/openhrt-2020-001471. PubMed 33741689 ↗
  • Hijazi Z, Wallentin L, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Granger CB, Lopes RD, Pol T, Yusuf S, Oldgren J, Siegbahn A. Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation. J Am Heart Assoc. 2020 Dec 15;9(24):e018984. doi: 10.1161/JAHA.120.018984. Epub 2020 Dec 9. PubMed 33292046 ↗
  • Wallentin L, Lindback J, Eriksson N, Hijazi Z, Eikelboom JW, Ezekowitz MD, Granger CB, Lopes RD, Yusuf S, Oldgren J, Siegbahn A. Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation. Eur Heart J. 2020 Nov 1;41(41):4037-4046. doi: 10.1093/eurheartj/ehaa697. PubMed 32984892 ↗
  • Hijazi Z, Granger CB, Hohnloser SH, Westerbergh J, Lindback J, Alexander JH, Keltai M, Parkhomenko A, Lopez-Sendon JL, Lopes RD, Siegbahn A, Wallentin L. Association of Different Estimates of Renal Function With Cardiovascular Mortality and Bleeding in Atrial Fibrillation. J Am Heart Assoc. 2020 Sep 15;9(18):e017155. doi: 10.1161/JAHA.120.017155. Epub 2020 Aug 31. PubMed 32865097 ↗
  • Zeitouni M, Giczewska A, Alexander JH. Reply: Specifics of Dose Modification in ARISTOTLE. J Am Coll Cardiol. 2020 Jul 7;76(1):128-129. doi: 10.1016/j.jacc.2020.05.013. No abstract available. PubMed 32616154 ↗
  • Rosjo H, Hijazi Z, Omland T, Westerbergh J, Lyngbakken MN, Alexander JH, Gersh BJ, Granger CB, Hylek EM, Lopes RD, Siegbahn A, Wallentin L. Cardiac troponin is associated with cardiac outcomes in men and women with atrial fibrillation, insights from the ARISTOTLE trial. J Intern Med. 2020 Aug;288(2):248-259. doi: 10.1111/joim.13072. Epub 2020 May 18. PubMed 32350915 ↗
  • Zeitouni M, Giczewska A, Lopes RD, Wojdyla DM, Christersson C, Siegbahn A, De Caterina R, Steg PG, Granger CB, Wallentin L, Alexander JH; ARISTOTLE Investigators. Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial. J Am Coll Cardiol. 2020 Mar 17;75(10):1145-1155. doi: 10.1016/j.jacc.2019.12.060. PubMed 32164888 ↗
  • Stanifer JW, Pokorney SD, Chertow GM, Hohnloser SH, Wojdyla DM, Garonzik S, Byon W, Hijazi Z, Lopes RD, Alexander JH, Wallentin L, Granger CB. Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease. Circulation. 2020 Apr 28;141(17):1384-1392. doi: 10.1161/CIRCULATIONAHA.119.044059. Epub 2020 Mar 12. PubMed 32160801 ↗
  • Garcia DA, Fisher DA, Mulder H, Wruck L, De Caterina R, Halvorsen S, Granger CB, Held C, Wallentin L, Alexander JH, Lopes RD. Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Am Heart J. 2020 Mar;221:1-8. doi: 10.1016/j.ahj.2019.10.013. Epub 2019 Oct 31. PubMed 31896036 ↗
  • Dalgaard F, Mulder H, Wojdyla DM, Lopes RD, Held C, Alexander JH, De Caterina R, Washam JB, Hylek EM, Garcia DA, Gersh BJ, Wallentin L, Granger CB, Al-Khatib SM. Patients With Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE Trial. Circulation. 2020 Jan 7;141(1):10-20. doi: 10.1161/CIRCULATIONAHA.119.041296. Epub 2019 Nov 21. PubMed 31747786 ↗
  • Goldstein SA, Green J, Huber K, Wojdyla DM, Lopes RD, Alexander JH, Vinereanu D, Wallentin L, Granger CB, Al-Khatib SM. Characteristics and Outcomes of Atrial Fibrillation in Patients With Thyroid Disease (from the ARISTOTLE Trial). Am J Cardiol. 2019 Nov 1;124(9):1406-1412. doi: 10.1016/j.amjcard.2019.07.046. Epub 2019 Aug 7. PubMed 31474328 ↗
  • Guimaraes PO, Pokorney SD, Lopes RD, Wojdyla DM, Gersh BJ, Giczewska A, Carnicelli A, Lewis BS, Hanna M, Wallentin L, Vinereanu D, Alexander JH, Granger CB. Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial. Clin Cardiol. 2019 May;42(5):568-571. doi: 10.1002/clc.23178. Epub 2019 Apr 9. PubMed 30907005 ↗
  • Washam JB, Hohnloser SH, Lopes RD, Wojdyla DM, Vinereanu D, Alexander JH, Gersh BJ, Hanna M, Horowitz J, Hylek EM, Xavier D, Verheugt FWA, Wallentin L, Granger CB; ARISTOTLE Committees and Investigators. Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial. J Thromb Thrombolysis. 2019 Apr;47(3):345-352. doi: 10.1007/s11239-019-01823-y. PubMed 30790160 ↗
  • Hohnloser SH, Fudim M, Alexander JH, Wojdyla DM, Ezekowitz JA, Hanna M, Atar D, Hijazi Z, Bahit MC, Al-Khatib SM, Lopez-Sendon JL, Wallentin L, Granger CB, Lopes RD. Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight. Circulation. 2019 May 14;139(20):2292-2300. doi: 10.1161/CIRCULATIONAHA.118.037955. PubMed 30773022 ↗
  • Alexander KP, Brouwer MA, Mulder H, Vinereanu D, Lopes RD, Proietti M, Al-Khatib SM, Hijazi Z, Halvorsen S, Hylek EM, Verheugt FWA, Alexander JH, Wallentin L, Granger CB; ARISTOTLE Investigators. Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial. Am Heart J. 2019 Feb;208:123-131. doi: 10.1016/j.ahj.2018.09.017. Epub 2018 Nov 22. PubMed 30579505 ↗
  • Sandhu RK, Ezekowitz JA, Hijazi Z, Westerbergh J, Aulin J, Alexander JH, Granger CB, Halvorsen S, Hanna MS, Lopes RD, Siegbahn A, Wallentin L. Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial. Open Heart. 2018 Nov 1;5(2):e000908. doi: 10.1136/openhrt-2018-000908. eCollection 2018. PubMed 30487982 ↗
  • Christersson C, Wallentin L, Andersson U, Alexander JH, Alings M, De Caterina R, Gersh BJ, Granger CB, Halvorsen S, Hanna M, Huber K, Hylek EM, Lopes RD, Oh BH, Siegbahn A. Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation. Heart. 2019 Feb;105(3):235-242. doi: 10.1136/heartjnl-2018-313351. Epub 2018 Sep 12. PubMed 30209126 ↗
  • Horowitz JD, De Caterina R, Heresztyn T, Alexander JH, Andersson U, Lopes RD, Steg PG, Hylek EM, Mohan P, Hanna M, Jansky P, Granger CB, Wallentin L; ARISTOTLE Investigators. Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation: An ARISTOTLE Substudy. J Am Coll Cardiol. 2018 Aug 14;72(7):721-733. doi: 10.1016/j.jacc.2018.05.058. PubMed 30092948 ↗
  • Sharma A, Hijazi Z, Andersson U, Al-Khatib SM, Lopes RD, Alexander JH, Held C, Hylek EM, Leonardi S, Hanna M, Ezekowitz JA, Siegbahn A, Granger CB, Wallentin L. Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation. Circulation. 2018 Oct 16;138(16):1666-1676. doi: 10.1161/CIRCULATIONAHA.118.034125. PubMed 29871978 ↗
  • Kopin D, Jones WS, Sherwood MW, Wojdyla DM, Wallentin L, Lewis BS, Verheugt FWA, Vinereanu D, Bahit MC, Halvorsen S, Huber K, Parkhomenko A, Granger CB, Lopes RD, Alexander JH. Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial. Am Heart J. 2018 Mar;197:133-141. doi: 10.1016/j.ahj.2017.11.005. Epub 2017 Nov 10. PubMed 29447773 ↗
  • Pol T, Held C, Westerbergh J, Lindback J, Alexander JH, Alings M, Erol C, Goto S, Halvorsen S, Huber K, Hanna M, Lopes RD, Ruzyllo W, Granger CB, Hijazi Z. Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial. J Am Heart Assoc. 2018 Feb 1;7(3):e007444. doi: 10.1161/JAHA.117.007444. PubMed 29419390 ↗
  • Goto S, Merrill P, Wallentin L, Wojdyla DM, Hanna M, Avezum A, Easton JD, Harjola VP, Huber K, Lewis BS, Parkhomenko A, Zhu J, Granger CB, Lopes RD, Alexander JH. Antithrombotic therapy use and clinical outcomes following thrombo-embolic events in patients with atrial fibrillation: insights from ARISTOTLE. Eur Heart J Cardiovasc Pharmacother. 2018 Apr 1;4(2):75-81. doi: 10.1093/ehjcvp/pvy002. PubMed 29385429 ↗
  • Vinereanu D, Wang A, Mulder H, Lopes RD, Jansky P, Lewis BS, Gersh BJ, Avezum A, Hanna M, Held C, Wallentin L, Granger CB, Alexander JH. Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease. Heart. 2018 Aug;104(15):1292-1299. doi: 10.1136/heartjnl-2017-312272. Epub 2018 Jan 19. PubMed 29352007 ↗
  • Rao MP, Vinereanu D, Wojdyla DM, Alexander JH, Atar D, Hylek EM, Hanna M, Wallentin L, Lopes RD, Gersh BJ, Granger CB; Apixaban for Reduction in Stroke Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Investigators. Clinical Outcomes and History of Fall in Patients with Atrial Fibrillation Treated with Oral Anticoagulation: Insights From the ARISTOTLE Trial. Am J Med. 2018 Mar;131(3):269-275.e2. doi: 10.1016/j.amjmed.2017.10.036. Epub 2017 Nov 6. PubMed 29122636 ↗
  • Vinereanu D, Lopes RD, Mulder H, Gersh BJ, Hanna M, de Barros E Silva PGM, Atar D, Wallentin L, Granger CB, Alexander JH; ARISTOTLE Investigators. Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or Warfarin. Stroke. 2017 Dec;48(12):3266-3273. doi: 10.1161/STROKEAHA.117.017574. Epub 2017 Oct 31. PubMed 29089455 ↗
  • Hijazi Z, Oldgren J, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Held C, Hylek EM, Lopes RD, Yusuf S, Granger CB, Siegbahn A, Wallentin L; ARISTOTLE and RE-LY Investigators. A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score. Eur Heart J. 2018 Feb 7;39(6):477-485. doi: 10.1093/eurheartj/ehx584. PubMed 29069359 ↗
  • Hijazi Z, Lindahl B, Oldgren J, Andersson U, Lindback J, Granger CB, Alexander JH, Gersh BJ, Hanna M, Harjola VP, Hylek EM, Lopes RD, Siegbahn A, Wallentin L. Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time. J Am Heart Assoc. 2017 Jun 23;6(6):e004851. doi: 10.1161/JAHA.116.004851. PubMed 28645934 ↗
  • Lopes RD, Guimaraes PO, Kolls BJ, Wojdyla DM, Bushnell CD, Hanna M, Easton JD, Thomas L, Wallentin L, Al-Khatib SM, Held C, Gabriel Melo de Barros E Silva P, Alexander JH, Granger CB, Diener HC. Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy. Blood. 2017 Jun 1;129(22):2980-2987. doi: 10.1182/blood-2016-08-731638. Epub 2017 Mar 29. PubMed 28356246 ↗
  • Cowper PA, Sheng S, Lopes RD, Anstrom KJ, Stafford JA, Davidson-Ray L, Al-Khatib SM, Ansell J, Dorian P, Husted S, McMurray JJV, Steg PG, Alexander JH, Wallentin L, Granger CB, Mark DB. Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial. JAMA Cardiol. 2017 May 1;2(5):525-534. doi: 10.1001/jamacardio.2017.0065. PubMed 28355434 ↗
  • Hu PT, Lopes RD, Stevens SR, Wallentin L, Thomas L, Alexander JH, Hanna M, Lewis BS, Verheugt FW, Granger CB, Jones WS. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial. J Am Heart Assoc. 2017 Jan 17;6(1):e004699. doi: 10.1161/JAHA.116.004699. PubMed 28096100 ↗
  • Bahit MC, Lopes RD, Wojdyla DM, Held C, Hanna M, Vinereanu D, Hylek EM, Verheugt F, Goto S, Alexander JH, Wallentin L, Granger CB. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. Heart. 2017 Apr;103(8):623-628. doi: 10.1136/heartjnl-2016-309901. Epub 2016 Oct 24. PubMed 27798052 ↗
  • Oldgren J, Hijazi Z, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Granger CB, Hylek EM, Lopes RD, Siegbahn A, Yusuf S, Wallentin L; RE-LY and ARISTOTLE Investigators. Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. Circulation. 2016 Nov 29;134(22):1697-1707. doi: 10.1161/CIRCULATIONAHA.116.022802. Epub 2016 Aug 28. PubMed 27569438 ↗
  • Alexander JH, Andersson U, Lopes RD, Hijazi Z, Hohnloser SH, Ezekowitz JA, Halvorsen S, Hanna M, Commerford P, Ruzyllo W, Huber K, Al-Khatib SM, Granger CB, Wallentin L; Apixaban for Reduction of Stroke and Other Thromboembolic Complications in Atrial Fibrillation (ARISTOTLE) Investigators. Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2016 Sep 1;1(6):673-81. doi: 10.1001/jamacardio.2016.1829. PubMed 27463942 ↗
  • Hijazi Z, Hohnloser SH, Andersson U, Alexander JH, Hanna M, Keltai M, Parkhomenko A, Lopez-Sendon JL, Lopes RD, Siegbahn A, Granger CB, Wallentin L. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial. JAMA Cardiol. 2016 Jul 1;1(4):451-60. doi: 10.1001/jamacardio.2016.1170. PubMed 27438322 ↗
  • Jaspers Focks J, Brouwer MA, Wojdyla DM, Thomas L, Lopes RD, Washam JB, Lanas F, Xavier D, Husted S, Wallentin L, Alexander JH, Granger CB, Verheugt FW. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. BMJ. 2016 Jun 15;353:i2868. doi: 10.1136/bmj.i2868. PubMed 27306620 ↗
  • Hijazi Z, Oldgren J, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Held C, Hylek EM, Lopes RD, Siegbahn A, Yusuf S, Granger CB, Wallentin L; ARISTOTLE and RE-LY Investigators. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet. 2016 Jun 4;387(10035):2302-2311. doi: 10.1016/S0140-6736(16)00741-8. Epub 2016 Apr 4. PubMed 27056738 ↗
  • Hijazi Z, Lindback J, Alexander JH, Hanna M, Held C, Hylek EM, Lopes RD, Oldgren J, Siegbahn A, Stewart RA, White HD, Granger CB, Wallentin L; ARISTOTLE and STABILITY Investigators. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J. 2016 May 21;37(20):1582-90. doi: 10.1093/eurheartj/ehw054. Epub 2016 Feb 25. PubMed 26920728 ↗
  • Hijazi Z, Aulin J, Andersson U, Alexander JH, Gersh B, Granger CB, Hanna M, Horowitz J, Hylek EM, Lopes RD, Siegbahn A, Wallentin L; ARISTOTLE Investigators. Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation. Heart. 2016 Apr;102(7):508-17. doi: 10.1136/heartjnl-2015-308887. Epub 2016 Feb 2. PubMed 26839066 ↗
  • Rao MP, Halvorsen S, Wojdyla D, Thomas L, Alexander JH, Hylek EM, Hanna M, Bahit MC, Lopes RD, De Caterina R, Erol C, Goto S, Lanas F, Lewis BS, Husted S, Gersh BJ, Wallentin L, Granger CB; Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Steering Committee and Investigators. Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. J Am Heart Assoc. 2015 Dec 1;4(12):e002015. doi: 10.1161/JAHA.115.002015. Erratum In: J Am Heart Assoc. 2021 Feb 16;10(4):e014653. doi: 10.1161/JAHA.119.014653. PubMed 26627878 ↗
  • Vinereanu D, Stevens SR, Alexander JH, Al-Khatib SM, Avezum A, Bahit MC, Granger CB, Lopes RD, Halvorsen S, Hanna M, Husted S, Hylek EM, Margulescu AD, Wallentin L, Atar D. Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial. Eur Heart J. 2015 Dec 7;36(46):3268-75. doi: 10.1093/eurheartj/ehv447. Epub 2015 Sep 14. PubMed 26371113 ↗
  • Avezum A, Lopes RD, Schulte PJ, Lanas F, Gersh BJ, Hanna M, Pais P, Erol C, Diaz R, Bahit MC, Bartunek J, De Caterina R, Goto S, Ruzyllo W, Zhu J, Granger CB, Alexander JH. Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Circulation. 2015 Aug 25;132(8):624-32. doi: 10.1161/CIRCULATIONAHA.114.014807. Epub 2015 Jun 23. PubMed 26106009 ↗
  • Held C, Hylek EM, Alexander JH, Hanna M, Lopes RD, Wojdyla DM, Thomas L, Al-Khalidi H, Alings M, Xavier D, Ansell J, Goto S, Ruzyllo W, Rosenqvist M, Verheugt FW, Zhu J, Granger CB, Wallentin L. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. Eur Heart J. 2015 May 21;36(20):1264-72. doi: 10.1093/eurheartj/ehu463. Epub 2014 Dec 12. PubMed 25499871 ↗
  • Hijazi Z, Siegbahn A, Andersson U, Lindahl B, Granger CB, Alexander JH, Atar D, Gersh BJ, Hanna M, Harjola VP, Horowitz J, Husted S, Hylek EM, Lopes RD, McMurray JJ, Wallentin L. Comparison of cardiac troponins I and T measured with high-sensitivity methods for evaluation of prognosis in atrial fibrillation: an ARISTOTLE substudy. Clin Chem. 2015 Feb;61(2):368-78. doi: 10.1373/clinchem.2014.226936. Epub 2014 Dec 1. PubMed 25451868 ↗
  • Garcia D, Alexander JH, Wallentin L, Wojdyla DM, Thomas L, Hanna M, Al-Khatib SM, Dorian P, Ansell J, Commerford P, Flaker G, Lanas F, Vinereanu D, Xavier D, Hylek EM, Held C, Verheugt FW, Granger CB, Lopes RD. Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. Blood. 2014 Dec 11;124(25):3692-8. doi: 10.1182/blood-2014-08-595496. Epub 2014 Oct 15. PubMed 25320240 ↗
  • Wallentin L, Hijazi Z, Andersson U, Alexander JH, De Caterina R, Hanna M, Horowitz JD, Hylek EM, Lopes RD, Asberg S, Granger CB, Siegbahn A; ARISTOTLE Investigators. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation. 2014 Nov 18;130(21):1847-58. doi: 10.1161/CIRCULATIONAHA.114.011204. Epub 2014 Oct 7. PubMed 25294786 ↗
  • Hijazi Z, Siegbahn A, Andersson U, Granger CB, Alexander JH, Atar D, Gersh BJ, Mohan P, Harjola VP, Horowitz J, Husted S, Hylek EM, Lopes RD, McMurray JJ, Wallentin L; ARISTOTLE Investigators. High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation. 2014 Feb 11;129(6):625-34. doi: 10.1161/CIRCULATIONAHA.113.006286. Epub 2013 Nov 13. PubMed 24226808 ↗
  • Flaker G, Lopes RD, Al-Khatib SM, Hermosillo AG, Hohnloser SH, Tinga B, Zhu J, Mohan P, Garcia D, Bartunek J, Vinereanu D, Husted S, Harjola VP, Rosenqvist M, Alexander JH, Granger CB; ARISTOTLE Committees and Investigators. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol. 2014 Mar 25;63(11):1082-7. doi: 10.1016/j.jacc.2013.09.062. Epub 2013 Nov 6. PubMed 24211508 ↗
  • Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Alexander JH, Atar D, Gersh BJ, Hanna M, Harjola VP, Horowitz JD, Husted S, Hylek EM, Lopes RD, McMurray JJ, Granger CB; ARISTOTLE Investigators. High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. J Am Coll Cardiol. 2014 Jan 7-14;63(1):52-61. doi: 10.1016/j.jacc.2013.07.093. Epub 2013 Sep 19. PubMed 24055845 ↗
  • Alexander JH, Levy E, Lawrence J, Hanna M, Waclawski AP, Wang J, Califf RM, Wallentin L, Granger CB. Documentation of study medication dispensing in a prospective large randomized clinical trial: experiences from the ARISTOTLE Trial. Am Heart J. 2013 Sep;166(3):559-65. doi: 10.1016/j.ahj.2013.05.025. Epub 2013 Aug 15. PubMed 24016507 ↗
  • Garcia DA, Wallentin L, Lopes RD, Thomas L, Alexander JH, Hylek EM, Ansell J, Hanna M, Lanas F, Flaker G, Commerford P, Xavier D, Vinereanu D, Yang H, Granger CB. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. Am Heart J. 2013 Sep;166(3):549-58. doi: 10.1016/j.ahj.2013.05.016. Epub 2013 Jul 25. PubMed 24016506 ↗
  • Wallentin L, Lopes RD, Hanna M, Thomas L, Hellkamp A, Nepal S, Hylek EM, Al-Khatib SM, Alexander JH, Alings M, Amerena J, Ansell J, Aylward P, Bartunek J, Commerford P, De Caterina R, Erol C, Harjola VP, Held C, Horowitz JD, Huber K, Husted S, Keltai M, Lanas F, Lisheng L, McMurray JJ, Oh BH, Rosenqvist M, Ruzyllo W, Steg PG, Vinereanu D, Xavier D, Granger CB; Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Investigators. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation. 2013 Jun 4;127(22):2166-76. doi: 10.1161/CIRCULATIONAHA.112.142158. Epub 2013 May 2. PubMed 23640971 ↗
  • McMurray JJ, Ezekowitz JA, Lewis BS, Gersh BJ, van Diepen S, Amerena J, Bartunek J, Commerford P, Oh BH, Harjola VP, Al-Khatib SM, Hanna M, Alexander JH, Lopes RD, Wojdyla DM, Wallentin L, Granger CB; ARISTOTLE Committees and Investigators. Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial. Circ Heart Fail. 2013 May;6(3):451-60. doi: 10.1161/CIRCHEARTFAILURE.112.000143. Epub 2013 Apr 10. PubMed 23575255 ↗
  • Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Christersson C, Ezekowitz J, Gersh BJ, Hanna M, Hohnloser S, Horowitz J, Huber K, Hylek EM, Lopes RD, McMurray JJ, Granger CB. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol. 2013 Jun 4;61(22):2274-84. doi: 10.1016/j.jacc.2012.11.082. Epub 2013 Apr 3. PubMed 23563134 ↗
  • Lopes RD, Al-Khatib SM, Wallentin L, Yang H, Ansell J, Bahit MC, De Caterina R, Dorian P, Easton JD, Erol C, Ezekowitz JA, Gersh BJ, Granger CB, Hohnloser SH, Horowitz J, Hylek EM, McMurray JJ, Mohan P, Vinereanu D, Alexander JH. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lancet. 2012 Nov 17;380(9855):1749-58. doi: 10.1016/S0140-6736(12)60986-6. Epub 2012 Oct 2. Erratum In: Lancet. 2013 Jan 19;381(9862):204. PubMed 23036896 ↗
  • Easton JD, Lopes RD, Bahit MC, Wojdyla DM, Granger CB, Wallentin L, Alings M, Goto S, Lewis BS, Rosenqvist M, Hanna M, Mohan P, Alexander JH, Diener HC; ARISTOTLE Committees and Investigators. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol. 2012 Jun;11(6):503-11. doi: 10.1016/S1474-4422(12)70092-3. Epub 2012 May 8. Erratum In: Lancet Neurol. 2012 Dec;11(12):1021. PubMed 22572202 ↗
  • Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep 15;365(11):981-92. doi: 10.1056/NEJMoa1107039. Epub 2011 Aug 27. PubMed 21870978 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2006 to primary completion in May 2011, 52 months.

Results were first posted in Apr 2013, 1 year 11 months after primary completion.

Of 83 phase 3 interventional studies under Atrial Fibrillation, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 63. This study's 52 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2006
First posted
Dec 19, 2006
StartActual
Dec 31, 2006
Primary completionActual
May 25, 2011
CompletionActual
May 25, 2011
Results first posted
Apr 29, 2013
Last update
Jul 3, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00412984
Responsible party
Sponsor
First posted
Dec 19, 2006
Start date
Dec 31, 2006
Primary completion
May 25, 2011
Completion
May 25, 2011
Results posted
Apr 29, 2013
Last update
Jul 3, 2018

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apixaban

Start the discussion